Journals / Bakırköy Tıp Dergisi / 2010 / Cilt: 6 - Sayı: 4

Botulinum toxin type A application in dystonia

Distonide botulinum toksini tip A uygulaması

Pages
137–141
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Botulinum A toxin treatment is safe and effective for all dystonia types, especially HFS and BFS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Botulinum toxin (BTX) causes muscle paralysis by blocking acetylcholine secretion at the neuromuscular junctions.
📊
Key Findings & Data:Material and Methods: Fiftyseven dystonia patients, who admitted to our outpatient clinics between July 2007-August 2009, were injected by Botulinum type A.
💡
Conclusion & Impact:Conclusion: Botulinum A toxin treatment is safe and effective for all dystonia types, especially HFS and BFS.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Botulinum toxin (BTX) causes muscle paralysis by blocking acetylcholine secretion at the neuromuscular junctions. In this study, results of BTX applications in our neurology department were described. Analysis of dystonia patients and the duration of BTX efficacy were investigated. Material and Methods: Fiftyseven dystonia patients, who admitted to our outpatient clinics between July 2007-August 2009, were injected by Botulinum type A. In this treatment, dental injector for the neck and extremity muscles, insulin injectors for the facial muscles were used. Statistically, Student t-test was applied. Results were considered significant at the level of p<0,05. Results: The patients aged between 23-86 years (51,23±13,98) and 33 of them were women. Twenty four patients had hemifacial spasm (HFS), 20 had cervical dystonia, 4 blepharospasm (BFS), 3 familial spastic paraparesis, 2 idiopathic focal dystonia, 2 writing cramp, and 2 post-stroke spasticity. It was revealed that average reinjection time for the HFS and BFS groups was 7,11±3,55 months, average reinjection time for the rest of the group was 5,78±2,73 months. Although reinjection time for the HFS and BFS groups were determined longer than the rest of the group, statistically there was no significant difference (p>0,05). Conclusion: Botulinum A toxin treatment is safe and effective for all dystonia types, especially HFS and BFS.

Özet

Amaç: Botulinum toksini (BTX), sinir terminallerinde asetil kolin salınımını inhibe ederek kas paralizisi oluşturur. Bu çalışmada kliniğimizde BTX uygulamalarının sonuçları değerlendirildi. Distoni hastalarının dağılımı ve BTX’den yararlanma süreleri incelendi. Gereç ve Yöntem: Temmuz 2007-Ağustos 2009 arasında Nöroloji Kliniği’ne başvuran 57 distoni hastasına Botulinum A toksini uygulandı. Uygulamada boyun ve ekstremite kasları için dental, yüz kasları için insülin enjektörü seçildi. İstatistiksel olarak Student t testi kullanıldı, anlamlılık p 0,05). Sonuç: Botulinum A toksini, özellikle HFS ve BFS olmak üzere, tüm distonilerin tedavisinde etkili ve güvenli bir yöntemdir.

🔖

Cite This Article

ÇABALAR, M., YAYLA, V. A., YETKİN, T. (2010). Botulinum toxin type A application in dystonia. Bakırköy Tıp Dergisi, Cilt: 6 - Sayı: 4, 137–141. https://ajindex.com/articles/130516

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kimura K, Kimura H, Yokosawa N, et al. Negative chronotropic effect of botulinum toxin on neonatal rat cardiac myocytes. Biochem Biophys Res Commun 1998: 244: 275-279
  2. Cichon JV, McCaffrey TV, Litchy WJ, Knops JL. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 1995: 105: 144-148
  3. Niamtu J 3rd. Botulinum toxin A: a review of 1085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003: 61: 317-324
  4. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med, 1991: 324: 1186-1194
  5. Aoki R. The development of BOTOX –Its history and pharmacology. Pain Digest 1998: 337-341
  6. Van Emengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as “Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus” in Zeitschrift für Hygiene und Infektionskrankheiten 26: 1-56, 1897. Rev Infect Dis, 1979: 1: 701-719
  7. Atassi Z, Dressler D, Jankovic J, Blazer J. Justinus Kerner and the history of botulism The latest news in sience and therapeutics. Newsletter of internationale conference 2002: Hannover, Germany
  8. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophtalmol Soc 1981: 79: 734-770
  9. Heise GJ, Mullen MP. Oromandibular dystonia treated with botulinum toxin: Report of case. J Oral Maxillofac Surg 1995: 53: 332-335
  10. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol 1984; 102: 1464-1468
  11. Costa PG, Aoki L, Saraiva FP, Matayoshi S. Botulinum toxin in the treatment of facial dystonia: evaluation of its efficacy and patients’ satisfaction along the treatment. Arq Bras Oftalmol 2005; 68: 471-474
  12. Schellini SA, Matai O, Igami TZ, Padovani CR, Padovani CP. Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review. Arq Bras Oftalmol 2006; 69: 23-26
  13. Chang LB, Tsai CP, Liao KK, et al. Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm. Zhonghua Yi Xue Za Zhi 1999; 62: 1-5
  14. Berardelli A, Carta A, Stocchi F, Formica A, Agnoli A, Manfredi M. Botulinum A toxin injection in patients with blepharospasm, tortikollis and hemifacial spasm. Ital J Neurol Sci 1990; 11: 589-593
  15. Tan AK. Botulinum toxin for neurological disorders in a movement disorders c